Evidence map›Paper›PMID 33630181›Full record

ReviewCurrent pain and headache reports2021

Cannabis and Migraine: It's Complicated.

Laszlo L Mechtler, Fran M Gengo, Vincent H Bargnes

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pain and headache reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Natural Products Derived from Cannabis sativa for Pain Management.Handbook of experimental pharmacology · 2025
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Laszlo L MechtlerDent Neurologic Institute, 3980 Sheridan Drive, Suite 600, Amherst, NY, 14226, USA. lmechtler@dentinstitute.com.ORCID http://orcid.org/0000-0002-6105-9159
Fran M GengoDent Neurologic Institute, 3980 Sheridan Drive, Suite 300, Amherst, NY, 14226, USA.
Vincent H BargnesDent Neurologic Institute, 3980 Sheridan Drive, Suite 600, Amherst, NY, 14226, USA.
Dent Neurologic Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe use of cannabis for the treatment of migraine has become an area of interest with the legalization of medical cannabis in the USA. Understanding the mechanisms of cannabinoids, available studies, and best clinical recommendations is crucial for headache providers to best serve patients. RECENT

findingsPatients utilizing medical cannabis for migraine have reported improvement in migraine profile and common comorbidities. Reduction in prescription medication is also common, especially opioids. Side effects exist, with the majority being mild. Not enough data is available for specific dose recommendations, but THC and CBD appear to mediate these observed effects. The purpose of this article is twofold: review the limited research surrounding cannabis for migraine disease and reflect on clinical management experiences to provide recommendations that best capture the potential use of cannabis for migraine.

Indexed as

AnalgesicsAnimalsCannabisDose-Response Relationship, DrugDrug Administration RoutesDrug Evaluation, PreclinicalHumansMedical MarijuanaMigraine DisordersAnalgesicsMedical MarijuanaCannabisHeadacheMarijuanaMedical cannabisMedical marijuanaMigraine

Identifiers

PMID33630181
OpenAlexW3129435406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.